Bio-Techne Corporation TECH

NASDAQ · Healthcare · Biotechnology

$72.67

Close on Fri, 20 Nov 2026 · market value $11.4B

What the price is betting on

Priced for a lot to go right

At $73, the price assumes revenue grows about 20% a year for five years, from $1.2B to about $2.9B by FY2031. That is about twice what analysts expect for the next two years and about eight times the company's own last three years.

The price assumes20%
Analysts, next two years8%
Last 3 years2.4%

Revenue growth a year. The price figure comes from a reverse DCF at a 9.9% discount rate.

Track it and Parra checks each report against the path, and tells you when revenue falls behind it.

Own more than TECH? Check up to 5 of your stocks at once, free, no account.

0$1B$2B$3B$1.2B'23'24'25'26Sep '26'27'28'29'30'31What the price needsReportedAnalysts

Both sides

Three stories, three values

Bear

$33

Base

$39

Bull

$47

Today $73

  • Bear $33. Cash flow grows 5% a year for the next 5 years, slower than expected, then slows to long-run growth.
  • Base $39. Cash flow grows 8% a year for the next 5 years, as analysts expect, then slows to long-run growth.
  • Bull $47. Cash flow grows 11% a year for the next 5 years, faster than expected, then slows to long-run growth.

Stories set by rules from the company’s record.

Checkpoints

The revenue the price needs

  1. YearNeedsAnalysts expect
  2. FY2027$1.4B$1.3B, below the path
  3. FY2028$1.7B$1.4B, below the path
  4. FY2029$2B$1.6B, below the path
  5. FY2030$2.4B$1.7B, below the path
  6. FY2031$2.9B$2B, below the path

Each year's revenue at 20% growth from $1.2B in the 12 months to September 2026.

At a glance

Healthcare · Biotechnology · listed on NASDAQ

Revenue, FY2026
$1.2B
Growth, 3 years a year
2.4%
Cash margin
22%
Net debt
$24.4M
Shares, 3-year change
−3%
Dividend yield
0.4%

What other healthcare prices are betting on

Figures from company filings and end-of-day market data, as of the close on Fri, 20 Nov 2026; updated every trading day. This page shows what today's price assumes, not whether to buy or sell. Not investment advice.